Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:24 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Effect of Chronic Pain on Delay Discounting in Methadone Patients
NCT04473950 · University of California, San Francisco · PHASE1 · terminated · last registry update 2025-03-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The COVID-19 Pandemic prevented us from meeting target goals.” | – | Registry record, University of California, San Francisco |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against OPRK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-24Results posted on the registry: Baylor College of Medicine, Lemborexant 10 mg + Naltrexone (NCT05458609)
- 2026-03-19Results posted on the registry: Henry Ford Health System, Celecoxib + Hydrocodone-Acetaminophen (NCT03818932)
- 2026-03-16Phase 3 first posted: AgelessRx, Rapamycin + Naltrexone (NCT07475546)
- 2026-03-13Results posted on the registry: RAND, a drug against OPRK1 (NCT07072819)
- 2026-03-09Also stopped (withdrawn): Universidad Europea de Canarias, pharmacological treatment by Opioids (NCT06240390)
- 2026-03-09Results posted on the registry: National Cancer Institute (NCI), E7 TCR cells + Aldesleukin (NCT02858310)
- 2026-02-25Phase 3 first posted: Shenzhen Sciencare Medical Industries Co., Ltd., Naltrexone + placebo (NCT07433413)
- 2026-02-10Results posted on the registry: Henry Ford Health System, Celecoxib + Pregabalin (NCT05488847)
- 2026-02-10Results posted on the registry: Baylor College of Medicine, Ibuprofen + Hydrocodone/acetaminophen (NCT05640674)
- 2026-02-10Also stopped (terminated): Baylor College of Medicine, Ibuprofen + Hydrocodone/acetaminophen (NCT05640674)
- 2026-02-03Also stopped (suspended): Friends Research Institute, Inc., Buprenorphine/Naloxone (NCT03616236)
- 2026-01-16Phase 3 first posted: Emory University, Placebo + Oxycodone 5 mg (NCT07348627)
- 2026-01-15Also stopped (withdrawn): Massachusetts General Hospital, Buprenorphine/Naloxone (NCT04771689)
- 2026-01-14Results posted on the registry: Novo Nordisk A/S, Semaglutide + Orlistat (NCT05579249)
- 2025-12-31Also stopped (withdrawn): Massachusetts General Hospital, Buprenorphine/naloxone (NCT04091009)
- 2025-12-23Also stopped (withdrawn): Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), celgene + Corticosteroid (NCT06712290)
- 2025-12-23Results posted on the registry: The Cleveland Clinic, Oxycodone + Ketorolac (NCT03888144)
- 2025-12-22Phase 3 first posted: University of California, San Francisco, Pharmacologic Pain Management (NCT07296770)
- 2025-11-25Results posted on the registry: Stanford University, Norco 5Mg-325Mg Tablet + Tylenol 325Mg Caplet (NCT03584152)
- 2025-10-31Results posted on the registry: Montefiore Medical Center, BUP microdose induction + TAU (NCT05118204)
- 2025-10-27Results posted on the registry: Glenn-Milo Santos, Naltrexone Hydrochloride + Placebo (NCT04791969)
- 2025-10-03Results posted on the registry: University of Washington, a drug against OPRK1 (NCT04600414)
- 2025-09-16Also stopped (terminated): The University of Texas Health Science Center, Houston, Naltrexone (Vivitrol) + Bupropion (NCT06374290)
- 2025-09-12Results posted on the registry: Vifor Fresenius Medical Care Renal Pharma, Difelikefalin Injection + Placebo Injection (NCT05885737)
- 2025-09-11Results posted on the registry: Albert Einstein College of Medicine, Naloxone + Diazoxide (NCT03608163)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision